Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and i

Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Ove

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SG

Biotechnology investing is a strange corner of the market. A company can own a drug that may even

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a c

Shares of Sagimet Biosciences Inc. (NASDAQ: SGMT - Get Free Report) have been given a consensus rati

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with

All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2

All clinical trial sites identified and CRO retained Patient screening expected to begin in October

FOSTER CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Sagimet Biosciences NASDAQ: SGMT plans to begin a Phase III study of its oral fatty acid synthase, o

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to in

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the an

FOSTER CITY, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

SAN MATEO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clin

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc.

https://www.gov.uk/government/news/resmetirom-rezdiffra-authorised-to-treat-metabolic-dysfunction-as

Phase 1 clinical data poster selected as a Best of EASL 2026 presentationCombination of denifanstat

Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outp

Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despi

SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clini

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.33) per share which beat the anal

Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifa

Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne  Phase 3

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investor

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lo

Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to in

Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acqu